Cambridge, Massachusetts–based biotech QurAlis Corp., has appointed Bryan Boggs as head of regulatory affairs. In addition, Christopher Gerry Lohan will join as head of clinical operations, and Guzide Adhikari will take on the role of head of global supply chain management.
The company is focused on developing novel treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets.
The three new hires will “play a critical role as we advance our deep pipeline of novel therapeutics for ALS and beyond to help patients desperately in need of treatment options,” said QurAlis CEO Kasper Roet in a statement.
Boggs joins QurAlis from Eli Lilly, where he worked for more than 30 years. His most recent role at the company was director, global regulatory and pharmacovigilance.
Lohan has more than 20 years of clinical research experience. In his last role, he worked as the director of clinical operations at Avedro.
Adhikari joins QurAlis from Translate Bio, a Sanofi company, where he was the senior director, supply chain management.
QurAlis was founded in 2016 to develop precision therapeutics for ALS.
The company plans on launching its first clinical trial for QRL-201, its lead treatment candidate, in late 2022.
Filed Under: clinical trials, Drug Discovery, Neurological Disease
